IVBXF — Innovent Biologics Inc/ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 1774163 ·
Last close
$11.35
Market Cap
$19.75B
52W High
$12.35
52W Low
$9.10
ADV30
5,669
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 37,347,839,000 | 17,344,705,000 | 17,991,596,000 |
| Jun 2025 | — | — | — | — | 23,594,272,000 | 9,540,139,000 | 9,172,452,000 |
| Dec 2024 | — | — | — | — | 21,602,602,000 | 7,508,185,000 | 8,484,873,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-15,092,803,000
Inventory
$1,301,745,000
Receivables
—
ST Investments
$886,741,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,041,522,688
EBITDA
$1,310,151,936
Free Cash Flow
$3,228,137,984
Enterprise Value
$4,345,159,680
Total Cash
$18,231,445,504
Total Debt
$2,815,774,976
Shares Out
1,740,920,818
Trailing EPS
$0.07
Book Value
$1.64
ROE
5.0%
ROA
1.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,041,523,000 | 2,140,913,000 | 813,565,000 | 37,347,839,000 | 17,991,596,000 | — | 10,001,012,000 |
| Dec 2024 | 9,421,888,000 | 258,119,000 | -94,631,000 | 21,602,602,000 | 8,484,873,000 | — | 1,287,024,000 |
| Dec 2023 | 6,206,070,000 | -909,210,000 | -1,027,913,000 | 20,627,360,000 | 8,099,779,000 | — | 147,810,000 |
| Dec 2022 | 4,556,380,000 | -2,581,885,000 | -2,179,270,000 | 17,588,845,000 | 6,858,896,000 | — | -1,918,804,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SDMHF | Sartorius Stedim Biotech S.A./ADR | $19.56B | $201.00 | — |
| AMCR | Amcor plc | $19.96B | $43.18 | — |
| AMCCF | Amcor plc | $20.23B | $43.75 | — |
| IHICF | IHI Corporation/ADR | $19.13B | $18.05 | — |
| FTV | Fortive Corp | $18.96B | $62.20 | — |
News headlines (Yahoo Finance, 1h cache)
Innovent’s China Verzenios Deal and New Jaypirca Nod Might Change The Case For Investing In Eli Lilly (LLY)
2026-07-09 02:12 · Yahoo
Eli Lilly (LLY) After The China Verzenios Shift And The Valuation Debate
2026-07-07 21:17 · Yahoo
Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover
2026-07-07 03:19 · Yahoo
Lilly quietly hands Chinese partner its cancer drug
2026-07-06 00:37 · Yahoo
Eli Lilly and Innovent agree Verzenios commercialisation deal in China
2026-07-01 08:32 · Yahoo
Eli Lilly Hands China Sales Rights for Verzenio to Innovent
2026-06-30 17:02 · Yahoo
Eli Lilly transfers China rights for Verzenios to Innovent Biologics
2026-06-30 14:10 · Yahoo
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
2026-06-30 04:00 · Yahoo
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second
2026-06-25 00:00 · Yahoo
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
2026-06-22 00:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.